Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study
Sponsor: Chengdu Third People's Hospital
This PHASE1/PHASE2 trial investigates Anti-PD-1 Antibody and MSI-H and is currently actively recruiting participants. Chengdu Third People's Hospital leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1/PHASE2
Status: Unknown → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
May 2022 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chengdu Third People's Hospital
- First Affiliated Hospital of Chongqing Medical University
- Sichuan Cancer Hospital and Research Institute
- The Affiliated Hospital Of Southwest Medical University
- West China Hospital
- Yunnan Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .